In the recent CTN1301 trial (29) comparing different approaches of graft-versus-host disease (GVHD) prevention combined with myeloablative conditioning in patients with AML, the relapse rates were similar in the CD34-selected arm as compared to arms that received T cell–replete grafts, highlighting the relative GVL resistance of AML, the disease for which alloSCT is most commonly employed. This evidence concerns the gene CD34 and acute myeloid leukemia.